Oncology Meets Immunology: The Cancer-Immunity Cycle

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Cancer immunoediting: from immunosurveillance to tumor escape

2002 • 4,911 citations

Nivolumab plus Ipilimumab in Advanced Melanoma

2013 • 4,054 citations

Cancer immunotherapy comes of age

2011 • 3,453 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2013 • 3,290 citations

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

2013 • 3,217 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

2010 • 2,721 citations

The PD‐1 pathway in tolerance and autoimmunity

2010 • 2,064 citations

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

2012 • 1,925 citations

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

2005 • 1,746 citations

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

2011 • 1,570 citations

Combining immunotherapy and targeted therapies in cancer treatment

2012 • 1,430 citations

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

2012 • 1,274 citations

Tumor Antigens Recognized by T Lymphocytes

1994 • 1,238 citations

SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation

2004 • 1,128 citations

Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer

2005 • 940 citations

Commensal bacteria at the interface of host metabolism and the immune system

2013 • 869 citations

Cytokine patterns in patients with cancer: a systematic review

2013 • 836 citations

Dendritic-Cell-Based Therapeutic Cancer Vaccines

2013 • 779 citations

The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures

2013 • 779 citations

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

2013 • 774 citations

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

2013 • 709 citations

Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

2012 • 596 citations

Deciphering and Reversing Tumor Immune Suppression

2013 • 535 citations

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

2013 • 458 citations

Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

2011 • 450 citations

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

2013 • 420 citations

Epitope Landscape in Breast and Colorectal Cancer

2008 • 408 citations

Role of the PD-1 Pathway in the Immune Response

2012 • 393 citations

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

2013 • 390 citations

PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines

2012 • 383 citations

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

2012 • 357 citations

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

2012 • 320 citations

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

2013 • 300 citations

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

2013 • 265 citations

Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

2012 • 241 citations

Role of Chemokines and Chemokine Receptors in Shaping the Effector Phase of the Antitumor Immune Response

2012 • 240 citations

A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy

2012 • 234 citations

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

2013 • 200 citations

Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma

2013 • 192 citations

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

2013 • 192 citations

The role of B7 family molecules in hematologic malignancy

2012 • 178 citations

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

2012 • 173 citations

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).

2013 • 169 citations

CD103 or LFA-1 Engagement at the Immune Synapse between Cytotoxic T Cells and Tumor Cells Promotes Maturation and Regulates T-cell Effector Functions

2012 • 166 citations

Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases

2011 • 162 citations

The origins of cancer robustness and evolvability

2010 • 161 citations

Explaining why Gleevec is a specific and potent inhibitor of Abl kinase

2013 • 152 citations

Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).

2013 • 152 citations

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

2010 • 139 citations

Diet-Induced Obesity Alters Dendritic Cell Function in the Presence and Absence of Tumor Growth

2012 • 103 citations

Armed response: how dying cells influence T‐cell functions

2011 • 101 citations

Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties

2013 • 101 citations

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).

2013 • 99 citations

Tumor Necrosis Factor/Tumor Necrosis Factor Receptor Family Members That Positively Regulate Immunity

2006 • 99 citations

Turning Tumors into Vaccines: Co-opting the Innate Immune System

2013 • 97 citations

B-Raf and the inhibitors: from bench to bedside

2013 • 92 citations

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

2013 • 90 citations

Towards patient‐specific tumor antigen selection for vaccination

2002 • 86 citations

mTOR, linking metabolism and immunity

2012 • 86 citations

Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.

2012 • 84 citations

Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice

2013 • 81 citations

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

1996 • 80 citations

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

2013 • 75 citations

Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

2013 • 74 citations

New checkpoint inhibitors ride the immunotherapy tsunami

2013 • 74 citations

Cancer immunotherapy

2012 • 69 citations

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

2013 • 62 citations

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

2013 • 56 citations

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

2013 • 55 citations

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

2013 • 55 citations

Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase

2003 • 46 citations

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

2013 • 43 citations

Crizotinib in the Treatment of Non–Small-Cell Lung Cancer

2013 • 42 citations

Live-attenuatedListeria-based immunotherapy

2013 • 40 citations

Immunology Taught by Humans

2012 • 37 citations

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors.

2013 • 32 citations

Comprehensive Analysis of MHC Ligands in Clinical Material by Immunoaffinity-Mass Spectrometry

2013 • 14 citations

AMP-224, a Fusion Protein that Targets PD-1

2013 • 14 citations

Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development

2011 • 8 citations

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

2012 • 4 citations

Abstract #2410: CT-011, a humanized monoclonal antibody, interacts with the PD-1 receptor and modulates survival and trafficking signals in effector/memory T lymphocytes

2009 • 2 citations